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Background: The purpose of this study was to clarify the association between morphological 
phenotypes according to the predominance of emphysema and efficacy of long-acting musca-
rinic antagonist and β2 agonist bronchodilators in patients with chronic obstructive pulmonary 
disease (COPD).
Methods: Seventy-two patients with stable COPD treated with tiotropium (n = 41) or 
  salmeterol (n = 31) were evaluated for pulmonary function, dynamic hyperinflation following 
metronome-paced incremental hyperventilation, six-minute walking distance, and St George’s 
Respiratory Questionnaire (SGRQ) before and 2–3 months following treatment with tiotropium 
or   salmeterol. They were then visually divided into an emphysema dominant phenotype (n = 25 in 
the tiotropium-treated group and n = 22 in the salmeterol-treated group) and an emphysema 
nondominant phenotype on high-resolution computed tomography, and the efficacy of the two 
drugs in each phenotype was retrospectively analyzed.
Results: Tiotropium significantly improved airflow limitation, oxygenation, and respiratory 
impedance in both the emphysema dominant and emphysema nondominant phenotypes, and 
improved dynamic hyperinflation, exercise capacity, and SGRQ in the emphysema dominant 
phenotype but not in the emphysema nondominant phenotype. Salmeterol significantly improved 
total score for SGRQ in the emphysema phenotype, but no significant effects on other parameters 
were found for either of the phenotypes.
Conclusion: These findings suggest that tiotropium is more effective than salmeterol for airflow 
limitation regardless of emphysema dominance, and also can improve dynamic hyperinflation in 
the emphysema dominant phenotype, which results in further improvement of exercise capacity 
and health-related quality of life.
Keywords: emphysema, dynamic hyperinflation, long-acting β2 agonist, long-acting muscarinic 
antagonist, exercise capacity, quality of life
Introduction
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by 
  airflow limitation that is not fully reversible.1 The chronic airflow limitation is attributed 
to narrowing of the small airway lumen due to airway wall thickening, mucus hyper-
secretion, and airway collapsibility due to decreased lung elastic recoil pressure and 
loss of alveolar attachments. However, the relative contributions of these pathological 
changes toward airflow limitation vary between individuals, and the pathophysiological 
pathways that lead to emphysema and to small airway remodelling are independent 
of each other.2,3 We have already demonstrated that when patients with COPD were International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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classified into phenotypes according to the presence of 
apparent emphysematous changes and/or the presence of 
airway wall thickening on chest high-resolution computed 
tomography (HRCT), each phenotype showed some char-
acteristic clinical features.4,5 The emphysema nondominant 
phenotype, accounting for 22.7% of all the patients, showed 
milder disturbance of gas exchange and lung hyperinflation, 
and greater reversibility of airflow limitation responsive to 
short-acting β2-agonists as compared with the emphysema 
dominant phenotype.
Dynamic hyperinflation is an important phenom-
enon causing dyspnea and restricting exercise capacity in 
COPD.6,7 It has been shown that improvements in dyspnea 
on effort following bronchodilator therapy correlate well 
with reductions in lung hyperinflation, as indicated by 
increases in inspiratory capacity.8 It was demonstrated that 
the rate of change in inspiratory capacity during exercise, 
ie, dynamic hyperinflation, correlated best with diffusion 
capacity, and that the subgroup with a reduced diffusion 
capacity (DLCO), which may be an emphysema domi-
nant phenotype, had a significantly faster rate of dynamic 
hyperinflation, occurring early in exercise, than those with 
a preserved DLCO.7 These findings suggest that the differ-
ence in morphological features between the emphysema 
dominant and emphysema nondominant phenotypes may 
affect not only clinical features but also the therapeutic 
response to bronchodilators.
Of all the bronchodilators, the long-acting muscarinic 
antagonists are the most effective agents for COPD when 
used alone. It has been demonstrated that the increases in 
forced expiratory volume in one second (FEV1) and forced 
vital capacity (FVC) following treatment with tiotropium 
are greater than those following treatment with salmeterol, 
a long-acting β2-agonist.9,10 However, it has not been shown 
whether there are differences in efficacy between long-acting 
muscarinic antagonists and long-acting β2-agonists when 
patients with COPD are divided into emphysema dominant 
and emphysema nondominant phenotypes. The purpose of 
the present study was to clarify the association between 
morphological phenotypes according to the dominancy of 
emphysema on chest HRCT and the efficacy of a long-acting 
muscarinic antagonist or a long-acting β2-agonist in COPD 
patients. We retrospectively compared the therapeutic effi-
cacy of tiotropium and salmeterol on pulmonary function, 
dynamic hyperinflation, exercise capacity, and health-related 
quality of life in the emphysema dominant and nondominant 
phenotypes of COPD.
Materials and methods
subjects
We recruited consecutive symptomatic patients with stable 
COPD, who had not yet been treated with any long-acting 
muscarinic antagonist or long-acting β2-agonist, and were 
seen in the outpatient clinic of Shinshu University Hospital 
from February 2005 to July 2008. COPD was diagnosed in 
accordance with the GOLD (Global Initiative for Chronic 
Obstructive Lung Disease) guidelines.1 Exclusion criteria 
were any history of asthma or asthmatic symptoms, treat-
ment with oral steroids and/or long-term oxygen therapy, 
and respiratory tract infection or exacerbation during the pre-
ceding three months. Seventy-two patients underwent chest 
HRCT and pulmonary function tests, including respiratory 
impedance, dynamic hyperinflation following metronome-
paced incremental hyperventilation (MPIH), a six-minute 
walking test, and health-related quality of life evaluated by 
the Saint George’s Respiratory Questionnaire (SGRQ) before 
and 2–3 months following treatment with tiotropium 18 µg 
once daily or salmeterol 50 µg twice daily, while continuing 
their other current therapy without any changes in dose. Of 
these 72 patients, 30 in the tiotropium-treated group and   
27 patients in salmeterol-treated group were then enrolled 
in a randomized, open-label, comparative trial of the clinical 
efficacy of tiotropium and salmeterol in COPD, the results 
of which have not yet been reported. The rest of the patients 
were assigned to tiotropium or salmeterol purely on a clini-
cal basis. All subjects had smoking-related COPD without 
α1-antitrypsin deficiency, and had a smoking history of more 
than 30 pack-years. In total, 41 of the 72 patients were treated 
with tiotropium and 31 patients were treated with salmeterol. 
Severity of COPD, assessed according to GOLD guidelines, 
was stage 1 (n = 3), stage 2 (n = 200), stage 3 (n = 17), and 
stage 4 (n = 3) in the tiotropium-treated group, and stage 1 
(n = 4), stage 2 (n = 14), stage 3 (n = 10), and stage 4 (n = 3) 
in the salmeterol-treated group. There was no significant 
difference in severity of COPD between the two treatment 
groups. As current therapies, 16 patients were treated with 
inhaled corticosteroids and 20 with oral theophylline in the 
tiotropium-treated group, and 12 patients were treated with 
inhaled corticosteroids and 15 with oral theophylline in the 
salmeterol-treated group. Most of patients used short-acting 
beta-2-agonists as needed to relieve dyspnea 2–3 times per 
week, but did not use them on the day that the pulmonary 
function tests were performed. The study was approved by the 
institutional research ethics committee of Shinshu University 
School of Medicine.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Protocol
The 41 patients treated with tiotropium and the 31 patients 
treated with salmeterol were divided into an emphysema 
dominant phenotype and emphysema nondominant pheno-
type according to visual findings on chest HRCT. We retro-
spectively compared the efficacy of tiotropium or salmeterol 
in each phenotype on the basis of pulmonary function tests, 
including respiratory impedance evaluated using an impulse 
oscillation system, dynamic hyperinflation following MPIH, 
exercise capacity evaluated by a six-minute walking test, and 
SGRQ. The six-minute walking test was performed according 
to American Thoracic Society guidelines.11 These evalua-
tions were done between 9 am and 11 am after inhalation of 
tiotropium or salmeterol, and repeated 2–3 months later.
evaluation of emphysema on chest hrCT
Evaluation for the presence of emphysema was done using a 
helical CT scanner (LightSpeed, General Electric, Milwaukee, 
WI) at full inspiration with 1–3 mm collimation (120 kVp, 
200 mA, pitch 1.0). HRCT images were photographed with 
a window setting appropriate for the lungs (window level 
-700 to -900 HU and width 800–1000 HU). The presence of 
emphysema on HRCT was defined as well demarcated areas 
of decreased attenuation in comparison with a contiguous nor-
mal lung and marginated by either a very thin wall (,1 mm) 
no wall at all, and/or multiple bullae (.1 cm) with an upper 
lung field predominance. Emphysema was scored visually in 
bilateral upper, middle, and lower lung fields according to the 
method used by Goddard et al.12 The score in each field was 
calculated for the dimensions according to the ratio of low 
attenuation area as follows: score 0, low attenuation area ,5%; 
score 1, 5% # low attenuation area ,25%; score 2, 25% # 
low attenuation area ,50%; score 3, 50% # low attenuation 
area ,75%; score 4, 75% # low attenuation area. The sever-
ity of emphysema was graded in accordance with the sum of 
scores for six dimensions as follows: grade 0, total score = 0; 
grade 1, total score = 1–6; grade 2, total score = 7–12; grade 3, 
total scores = 13–18; grade 4, total scores = 19–24. We defined 
that emphysema-dominant COPD had emphysema $ grade 2 
and that emphysema nondominant COPD was emphysema 
grade 0–1. Computed tomography images were analyzed 
independently by two pulmonologists (YK and KF) with no 
knowledge of the patients’ clinical status.
Pulmonary function tests
Spirometry  and  DLCO  were  measured  using  the 
Chestac-8800 (Chest Co Ltd, Tokyo, Japan).   Functional   
  residual capacity was measured using a Body Box   (Medgraphic, 
Ann Arbor, MI), after which the subject immediately inspired 
to total lung capacity and expired maximally to residual 
volume, allowing calculation of lung volume and residual 
volume/total lung capacity. Local Japanese reference data,13 
developed by the Japanese Respiratory Society, were used to 
derive predicted values for FEV1 and vital capacity, and pre-
dicted values for DLCO and lung volumes (functional residual 
capacity, residual volume, and total lung capacity) measured 
by body plethysmography were determined using the formulae 
of Nishida et al14 and Boren et al,15 respectively. Respiratory 
impedance was measured using an impulse oscillation system 
(Masterscreen, Erich Jaeger, Hoechberg, Germany), as previ-
ously described.16,17 Measurements of respiratory impedance 
were performed during tidal breath for 30 seconds in a sitting 
position, supporting the subject’s cheeks and mouth floor 
to reduce upper airway shunting. Respiratory impedance is 
characterized by two components, ie, respiratory resistance 
and reactance. Reactance undergoes a transition from nega-
tive to positive values as frequency (ƒ) increases. The resonant 
frequency (ƒres) was determined as the frequency at which 
reactance crossed zero and the elastic and inertial forces were 
equal in magnitude and opposite. Respiratory resistance and 
reactance at lower oscillation frequencies and respiratory 
resistance at higher frequencies were evaluated at oscillation 
frequencies of 5 Hz (Rrs5 and Xrs5) and 20 Hz (Rrs20). We 
also measured mean values of Rrs5 and Xrs5 separately for 
inspiration and expiration of tidal breath, and evaluated the 
difference between mean expiratory and inspiratory resistance 
(∆Rrs5) and reactance (∆Xrs5). Each subject was examined at 
least three times and the values were averaged.
Evaluation of dynamic hyperinflation 
following MPIh
Dynamic hyperinflation was evaluated by MPIH, incre-
mentally increasing the breathing rate from 20 to 30 and 
40 breaths per minute according to our previous report.18 
  End-expiratory lung volume was measured by body plethys-
mography, inspiratory capacity, and vital capacity immedi-
ately after breathing at a rate of 20 breaths per minute paced 
by a metronome for 30 seconds. Consequently, breathing 
rate was increased to 30 breaths per minute and 40 breaths 
per minute in 30-second increments, and end-expiratory 
lung volume, inspiratory capacity, and vital capacity were 
again measured immediately after MPIH for 30 seconds at 
each breathing rate. Inspiratory capacity at rates of 20, 30, 
and 40 breaths per minute were expressed as IC20, IC30, and International Journal of COPD 2011:6
Table 1 Characteristics of patients with chronic obstructive pulmonary disease in the tiotropium-treated and salmeterol-treated groups
Tiotropium-treated group Salmeterol-treated group
Emphysema  Nonemphysema Emphysema Nonemphysema
number 25 16 22 9
Age, years 75.3 ± 1.3 71.4 ± 1.8 72.6 ± 1.3 69.8 ± 2.5
gender, M/F 22/3 14/2 22/0 8/1
BMI, kg/m2 19.9 ± 0.5†† 23.4 ± 0.7 20.8 ± 0.5†† 24.8 ± 0.8
VC, % pred 89.0 ± 3.8 99.7 ± 4.3 96.3 ± 4.3 102.8 ± 6.5
IC, L 1.73 ± 0.10†,§ 2.25 ± 0.18 2.10 ± 0.11 2.41 ± 0.26
FeV1, % pred 48.3 ± 3.3†† 65.1 ± 3.3 50.7 ± 4.0† 72.4 ± 7.5
FeV1/FVC, % 45.1 ± 1.7†† 57.4 ± 2.2 45.4 ± 2.2†† 59.3 ± 3.8
FrC, % of pred 120.9 ± 6.8 120.9 ± 8.9 126.1 ± 7.2 125.5 ± 15.9
rV, % of pred 191.3 ± 13.8 165.0 ± 13.0 210.9 ± 14.9 179.7 ± 21.6
TLC, % pred 119.5 ± 4.3 117.7 ± 5.7 126.9 ± 5.2 118.1 ± 7.5
rV/TLC, % 54.3 ± 1.9 46.6 ± 2.5 52.2 ± 2.1 45.9 ± 3.1
DLCO, % pre. 49.0 ± 3.7†† 66.2 ± 3.6 54.5 ± 4.1† 75.0 ± 6.2
PaO2, Torr 65.1 ± 1.7 70.0 ± 1.6 66.4 ± 1.6† 73.7 ± 2.1
PaCO2, Torr 39.6 ± 1.0 39.3 ± 1.6 40.0 ± 0.8 39.6 ± 1.4
LAA score 18.5 ± 1.2†† 2.2 ± 0.5 18.6 ± 1.0†† 0.8 ± 0.7
Notes: †P , 0.05; ††P , 0.01 versus nonemphysema phenotype; §P , 0.05 versus salmeterol-treated group. Values are mean ± standard error of the mean. 
Abbreviations: BMI, body mass index; IC, inspiratory capacity; LAA, low attenuation area; rV, residual volume; TLC, total lung capacity; DLCO, 
carbon monoxide diffusion test; PaCO2, arterial carbon dioxide tension; PaO2, arterial oxygen tension; FeV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; pred, predicted.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
222
Fujimoto et al
IC40, respectively. Dynamic hyperinflation was evaluated by 
the decreases in inspiratory capacity from IC20 to IC30 (∆IC30; 
IC30–IC20) and from IC20 to IC40 (∆IC40; IC40–IC20).
Data analysis
The values shown in the text, figures, and tables represent the 
mean ± standard error of the mean. Comparison of variables 
at baseline and at the end of the study period was performed 
using paired t-tests. Simple correlations between variables 
were examined by calculating Pearson’s product correlation 
coefficient. Variables were compared using the Kruskal–
Wallis test, followed by multiple comparisons among groups 
in combination with phenotypes using the nonparametric 
Scheffe method. All statistical analyses were performed 
using Windows-compatible software (Stat Flex version 5.0; 
Artech, Osaka, Japan). A value of P , 0.05 was considered 
significant for the results of all statistical analyses.
Results
Characteristics of emphysema phenotypes 
before treatment with tiotropium  
or salmeterol
Twenty-five of 41 patients treated with tiotropium and 22 of 
31 patients treated with salmeterol were classified as having 
emphysema dominant COPD (the emphysema phenotype). 
The remaining patients, ie, 16 of 41 tiotropium-treated 
patients and nine of 31 salmeterol-treated patients, were 
classified as having emphysema nondominant COPD (the 
nonemphysema phenotype).
In both tiotropium-treated and salmeterol-treated patients, 
body mass index, FEV1, FEV1/FVC, and DLCO were sig-
nificantly lower for the emphysema phenotype than for the 
nonemphysema phenotype (Table 1). The mean values of 
inspiratory capacity and arterial oxygen tension (PaO2) were 
lower and residual volume/total lung capacity was higher in 
emphysema phenotype. There were significant differences 
in inspiratory capacity for the tiotropium-treated group and 
in PaO2 for the salmeterol-treated group. There were no sig-
nificant differences in low attenuation area scores between 
the tiotropium-treated and salmeterol-treated groups for 
either phenotype.
Pulmonary function tests
FEV1 and PaO2 were significantly increased, Rrs5 was sig-
nificantly decreased, and Xrs5 significantly less negative 
following treatment with tiotropium for both phenotypes 
(Table 2). The increase in PaO2 was significantly greater for 
the nonemphysema phenotype. Furthermore, Rrs5, Rrs20, 
and ƒres were decreased in the emphysema phenotype, and 
within-breath changes in Xrs5 were reduced significantly 
for the nonemphysema phenotype. There were no signifi-
cant   differences in improvement of these pulmonary func-
tion parameters, except for PaO2, between the phenotypes. 
There were no significant changes following treatment with International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 2 Effects of tiotropium or salmeterol on pulmonary function tests in emphysema and non-emphysema chronic obstructive 
pulmonary disease phenotypes
Emphysema phenotype Nonemphysema phenotype
Pre Post ΔPre-post Pre Post ΔPre-post
Tiotropium-treated group
FeV1, L 1.17 ± 0.09†† 1.25 ± 0.10*,†† 0.08 ± 0.03 1.71 ± 0.14 1.84 ± 0.16* 0.13 ± 0.05
FrC 4.31 ± 0.22 4.27 ± 0.20 -0.05 ± 0.14 3.86 ± 0.26 3.71 ± 0.24 -0.15 ± 0.13
rV 3.16 ± 0.22 3.12 ± 0.21 -0.04 ± 0.16 2.82 ± 0.24 2.59 ± 0.19 -0.23 ± 0.18
rV/TLC, % 53.2 ± 2.1 52.3 ± 2.3† -0.85 ± 1.49 46.6 ± 2.5 44.4 ± 2.0 -2.15 ± 2.24
PaO2 64.9 ± 1.7 67.3 ± 1.9*,†† 2.3 ± 1.1†† 69.1 ± 1.8 77.7 ± 2.8** 8.6 ± 2.0§
rrs5, kPa ⋅ s/L 0.44 ± 0.03 0.35 ± 0.02** -0.08 ± 0.03§§ 0.39 ± 0.04 0.32 ± 0.04* -0.07 ± 0.02
Rrs5-Rrs20, kPa ⋅ s/L 0.16 ± 0.03 0.10 ± 0.02** -0.06 ± 0.02 0.12 ± 0.03 0.06 ± 0.04 -0.07 ± 0.04
Xrs5, kPa ⋅ s/L -0.28 ± 0.04 -0.20 ± 0.02* 0.08 ± 0.04§ -0.21 ± 0.04 -0.16 ± 0.03* 0.05 ± 0.02
∆Xrs5, kPa ⋅ s/L -0.12 ± 0.04 -0.06 ± 0.03 0.07 ± 0.04§ -0.07 ± 0.05 -0.02 ± 0.03* 0.06 ± 0.03
ƒres, hz 30.9 ± 1.9†† 25.9 ± 1.6**,† -5.0 ± 1.3 22.6 ± 2.0 19.2 ± 2.1 -3.5 ± 2.0
Salmeterol-treated group
FeV1, L 1.31 ± 0.10† 1.34 ± 0.10† 0.02 ± 0.03 1.89 ± 0.26 1.89 ± 0.26 0.00 ± 0.04
FrC 4.63 ± 0.31 4.58 ± 0.27 -0.05 ± 0.16 3.72 ± 0.41 3.66 ± 0.28 -0.06 ± 0.33
rV 3.43 ± 0.29 3.27 ± 0.28 -0.17 ± 0.23 2.80 ± 0.39 2.50 ± 0.20 -0.30 ± 0.38
rV/TLC,% 51.8 ± 2.1 49.8 ± 2.6 -2.1 ± 1.8 45.9 ± 3.1 43.3 ± 3.0 -2.7 ± 3.2
PaO2, Torr 66.4 ± 1.6† 66.9 ± 1.6†† 0.5 ± 1.2 73.7 ± 2.1 76.0 ± 2.4 2.3 ± 1.6
rrs5, kPa ⋅ s/L 0.37 ± 0.04 0.40 ± 0.04 0.02 ± 0.02† 0.41 ± 0.04 0.34 ± 0.03 -0.07 ± 0.03
Rrs5-Rrs20, kPa ⋅ s/L 0.13 ± 0.03 0.13 ± 0.04 -0.00 ± 0.03 0.12 ± 0.02 0.07 ± 0.02 -0.05 ± 0.02
Xrs5, kPa ⋅ s/L -0.19 ± 0.03 -0.23 ± 0.03 -0.04 ± 0.02 -0.19 ± 0.04 -0.14 ± 0.03 0.04 ± 0.04
∆Xrs5, kPa ⋅ s/L -0.08 ± 0.03 -0.13 ± 0.05 -0.05 ± 0.04 -0.02 ± 0.03 0.02 ± 0.01 0.04 ± 0.03
ƒres, hz 27.4 ± 1.7 25.4 ± 1.8†† -2.0 ± 1.1† 24.1 ± 3.3 16.7 ± 2.0* 7.4 ± 2.4
Notes: Values are mean ± standard error of the mean. *P , 0.05 and **P , 0.01 versus pretreatment;  †P , 0.05 and  ††P , 0.01 versus nonemphysema phenotype,   
§P , 0.05 and §§P , 0.01 versus salmeterol-treated group. 
Abbreviations: rrs5 and rrs20, respiratory resistances at 5 hz and 20 hz frequencies; Xrs5, respiratory reactance at 5 hz frequencies; ∆Xrs5, within-breath changes in 
Xrs5; ƒres, resonant frequency; FrC, functional residual capacity; rV, residual volume; TLC, total lung capacity; PaO2, arterial oxygen tension; FeV1, forced expiratory volume 
in 1 second; FVC, forced vital capacity.
  salmeterol in any of the pulmonary function tests, except for 
ƒres in both phenotypes. On the whole, the efficacy of tiotro-
pium for pulmonary function was superior to that of salme-
terol for both phenotypes. Significant greater improvements 
in Rrs5, Xrs5, and ∆Xrs5 for the emphysema phenotype and 
in PaO2 for the nonemphysema phenotype were found after 
tiotropium than after salmeterol.
Dynamic hyperinflation following MPIH
Inspiratory capacity was incrementally decreased as breath-
ing rate was increased from 20 to 40 breaths per minute in 
all patients before treatment with tiotropium or salmeterol, 
regardless of phenotype (Table 3). In the tiotropium-
treated group, the inspiratory capacity at each breathing 
rate was significantly lower and dynamic hyperinflation, 
expressed as the decrease in inspiratory capacity follow-
ing MPIH (∆IC30 and ∆IC40), was significantly greater for 
the emphysema phenotype than for the nonemphysema 
phenotype. IC30 and IC40 were significantly increased and 
∆IC40 was significantly decreased following treatment with 
tiotropium for the emphysema phenotype, but not for the 
nonemphysema phenotype. It has been demonstrated that 
the extent of dynamic hyperinflation following exercise is 
affected by inspiratory capacity at baseline.7 Therefore, 
we corrected ∆IC30 and ∆IC40 by IC20, and expressed 
these as percentage decreases in inspiratory capacity,   
ie, as ∆IC30/IC20 and ∆IC40/IC20. Both ∆IC30/IC20 and ∆IC40/
IC20 were also significantly reduced following treatment 
with tiotropium only for the emphysema phenotype. There 
was a significant correlation between low attenuation 
area score and ∆IC40 (r = 0.40, P , 0.05) and ∆IC40/IC20 
(r = 0.39, P , 0.05) in the tiotropium-treated group. In 
the salmeterol-treated group, significant improvements in 
lung hyperinflation at each respiratory rate and dynamic 
hyperinflation following treatment could not be obtained 
for either phenotype.
Six-minute walking test and SGRQ
Patients with the emphysema phenotype showed severe 
desaturation during the walking test when compared with 
those having the nonemphysema phenotype (Table 4). 
  Six-minute walking distance was significantly increased International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 3 Effects of tiotropium or salmeterol on dynamic hyperinflation following metronome-paced incremental hyperventilation in 
emphysema and nonemphysema chronic obstructive pulmonary disease phenotypes
Emphysema phenotype Nonemphysema phenotype
Pre Post ΔPre-Post Pre Post ΔPre-post
Tiotropium-treated group
IC20, L 1.51 ± 0.09† 1.53 ± 0.10† 0.03 ± 0.06 1.90 ± 0.18 1.98 ± 0.16 0.08 ± 0.07
IC30, L 1.23 ± 0.09††,§ 1.37 ± 0.09*,†† 0.14 ± 0.06§ 1.80 ± 0.15 1.97 ± 0.17 0.17 ± 0.10
IC40, L 1.09 ± 0.08††,§ 1.26 ± 0.09**,† 0.17 ± 0.05§ 1.72 ± 0.17 1.74 ± 0.18 0.02 ± 0.11
∆IC30, L -0.28 ± 0.05†,§ -0.16 ± 0.04† 0.11 ± 0.06§§ -0.10 ± 0.06 -0.00 ± 0.05 0.09 ± 0.07
∆IC40, L -0.42 ± 0.06††,§ -0.28 ± 0.05* 0.14 ± 0.06†,§§ -0.14 ± 0.05 -0.21 ± 0.05 -0.07 ± 0.08
∆IC30/IC20, % -18.1 ± 2.7 -10.1 ± 2.2* 7.9 ± 3.6§ -2.4 ± 3.2 -0.6 ± 2.9 1.9 ± 4.5
∆IC40/IC20, % -27.3 ± 3.3 -18.0 ± 2.4* 9.3 ± 3.7†,§ -5.9 ± 3.1 -12.6 ± 3.8 -6.6 ± 5.9
Salmeterol-treated group
IC20, L 1.65 ± 0.12 1.75 ± 0.11 0.10 ± 0.08 2.02 ± 0.23 1.98 ± 0.24 -0.04 ± 0.08
IC30, L 1.57 ± 0.12 1.51 ± 0.10 -0.06 ± 0.05 1.87 ± 0.25 1.86 ± 0.21 -0.01 ± 0.08
IC40, L 1.44 ± 0.11 1.40 ± 0.09 -0.04 ± 0.07 1.68 ± 0.26 1.69 ± 0.20 0.01 ± 0.13
∆IC30, L -0.08 ± 0.06 -0.24 ± 0.05 -0.16 ± 0.08† -0.15 ± 0.05 -0.12 ± 0.06 0.03 ± 0.06
∆IC40, L -0.21 ± 0.07 -0.35 ± 0.06 -0.14 ± 0.09 -0.35 ± 0.12 -0.29 ± 0.11 0.05 ± 0.14
∆IC30/IC20, % -3.6 ± 4.8 -12.9 ± 2.8 -9.2 ± 5.6 -8.6 ± 2.5 -5.0 ± 3.1 3.6 ± 3.8
∆IC40/IC20, % -11.7 ± 5.5 -19.2 ± 2.6 -7.5 ± 6.0 -17.9 ± 4.8 -13.5 ± 5.2 4.4 ± 6.0
Notes: Values are mean ± standard error of the mean. *P , 0.05 and **P , 0.01 versus pretreatment; †P , 0.05 and ††P , 0.01 versus nonemphysema phenotype;   
§P , 0.05 and §§P , 0.01 versus salmeterol-treated group. 
Abbreviations: IC20, IC30, and IC40, inspiratory capacity at the each rate of 20, 30, and 40 breaths per minute; ∆IC30 and ∆IC40, decreases in IC from IC20 to IC30 (IC30–IC20) 
and from IC20 to IC40 (IC40–IC20).
following treatment with tiotropium for the emphysema 
  phenotype. However, significant increases in six-minute 
walking distance were not observed for the nonemphysema 
phenotype in the tiotropium-treated group or for either phe-
notype in the salmeterol-treated group.
Following treatment with tiotropium, the SGRQ score 
and the scores for the impact and symptom domains were 
significantly decreased by more than four points, represent-
ing the minimal clinically important difference, for the 
emphysema phenotype. In contrast, a significant decrease 
was observed only in the symptom domain score for the 
nonemphysema phenotype in the tiotropium-treated group. 
In the salmeterol-treated group, the total score was signifi-
cantly decreased for the emphysema phenotype. However, 
in the nonemphysema phenotype, only the scores for activ-
ity and symptom domains were significantly decreased. 
There were no significant differences in improvement of 
health-related quality of life according to phenotype or 
treatment group.
Discussion
Treatment with tiotropium for 2–3 months resulted in sig-
nificant improvements in airflow limitation, oxygenation, 
and respiratory impedance for both the emphysema domi-
nant and nondominant phenotypes of COPD. Furthermore, 
tiotropium significantly improved dynamic hyperinflation, 
exercise capacity, and health-related quality of life for the 
emphysema phenotype, but not for the emphysema nondomi-
nant phenotype. On the other hand, in the salmeterol-treated 
group, significant improvements in pulmonary function, 
dynamic hyperinflation, and exercise capacity could not be 
obtained for either phenotype. Only the total score on the 
SGRQ for the emphysema phenotype decreased significantly 
following treatment with salmeterol. These findings sug-
gest that tiotropium is more effective than salmeterol for 
airflow limitation, regardless of predominance of emphy-
sema, and also can improve dynamic hyperinflation in the 
emphysema dominant phenotype, which may contribute to 
further improvement in exercise capacity and health-related 
quality of life.
A limitation of this retrospective study is lack of sta-
tistical power because the sample size was small for the 
nonemphysema phenotype (n = 9 in the salmeterol-treated 
group and n = 16 in the tiotropium-treated group) which is 
generally lower, accounting for only about 22% of COPD. 
The other main limitation was that the assessment of emphy-
sema was done by a visual scoring method, rather than using 
software-based quantification of emphysema. However, the 
reproducibility of visual scoring had been demonstrated in 
our previous report.5International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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The efficacy of long-acting muscarinic antagonists for 
improving pulmonary function has been reported to be 
superior to that of long-acting β2-agonists,10,19 and greater 
improvements in pulmonary function following treatment 
with tiotropium were found when compared with use of sal-
meterol in our study. When the patients were divided accord-
ing to emphysema dominant and nondominant phenotypes, 
improvement in airflow limitation was found regardless of 
the predominance of emphysema.
Dynamic hyperinflation is usually evaluated by the 
decrease in inspiratory capacity during exercise. Gelb 
et al20 have demonstrated the utility of the metronome-
paced hyperventilation (MPH) technique for evaluation of 
dynamic hyperinflation, which is dependent on increasing 
breathing frequency. We have also demonstrated a stepwise 
decrease in inspiratory capacity consistent with increased 
end-expiratory lung volume following the incremental 
increase of breathing frequency from 20 to 40 breaths per 
minute in COPD, but not in never-smokers without COPD, 
and the dynamic hyperinflation following MPIH was 
reduced by the inhalation of a short-acting β2-agonist.18 
In this study, tiotropium significantly reduced dynamic 
hyperinflation in the emphysema phenotype but not in 
the nonemphysema phenotype. It has been demonstrated 
that the total extent of changes in inspiratory capacity 
  during exercise is determined primarily by resting volume 
  constraints, ie, inspiratory capacity at rest. However, the rate 
of change in inspiratory capacity during exercise correlated 
best with diffusion capacity, and the subgroup with greater 
lung hyperinflation and greater reduction in DLCO had a 
significantly faster rate of dynamic hyperinflation, occur-
ring early in exercise, than the subgroup with preserved 
DLCO.7 In this study, tiotropium-treated patients with the 
emphysema phenotype having lower inspiratory capacity 
and DLCO showed greater dynamic hyperinflation com-
pared with patients with the nonemphysema phenotype. 
Decreased lung elastic recoil and loss of alveolar attach-
ments due to alveolar destruction contribute importantly to 
airway collapsibility and closure during expiration, which 
may easily lead to dynamic hyperinflation.
O’Donnell et al21 demonstrated that treatment with tiotro-
pium for six weeks resulted in sustained reduction of end-expi-
ratory lung volume at rest and during exercise, and significantly 
improved both exertional dyspnea and exercise capacity in 96 
patients with moderate-to-severe COPD. Gelb et al20 evaluated 
dynamic hyperinflation by the decrease in inspiratory capacity 
following MPH at twice the resting respiratory rate for 20 sec-
onds in 60 COPD patients. They demonstrated that tiotropium 
Table 4 Effects of tiotropium or salmeterol on exercise capacity and St Georges’ Respiratory Questionnaire scores in emphysema and 
nonemphysema chronic obstructive pulmonary disease phenotypes
Emphysema phenotype Nonemphysema phenotype
Pre Post ΔPre-post Pre Post ΔPre-post
Tiotropium-treated group
6MWD, m 402.6 ± 19.8 428.9 ± 16.9** 26.3 ± 8.7 426.8 ± 23.6 451.4 ± 28.3 24.6 ± 14.2
Lowest spO2, % 88.6 ± 1.6† 87.9 ± 1.2† -0.7 ± 0.7 92.8 ± 0.7 92.0 ± 0.7 -0.8 ± 0.4
Prmax, beats/minute 113.6 ± 3.6 115.2 ± 3.2 1.5 ± 3.4 120.7 ± 4.6 125.3 ± 6.0 4.6 ± 3.8
Bsmax 5.2 ± 0.6 5.8 ± 0.5††§§ 0.5 ± 0.5§§ 3.4 ± 0.7 3.2 ± 0.6 -0.2 ± 0.6
symptom 55.3 ± 3.6 46.6 ± 3.5* -8.7 ± 3.7 46.0 ± 5.3 35.3 ± 4.2* -10.7 ± 4.1
Active 64.5 ± 4.0§ 56.3 ± 4.3† -8.2 ± 4.5 7.9 ± 11.0 36.3 ± 8.2 -11.6 ± 6.6
Impact 29.9 ± 3.2 24.2 ± 2.9* -5.6 ± 2.5 19.5 ± 5.4 15.2 ± 3.9 -4.3 ± 4.1
Total 46.7 ± 3.0 39.4 ± 2.7**,† -7.2 ± 2.3 35.1 ± 6.4 26.9 ± 4.6 -8.2 ± 4.2
Salmeterol-treated group
6MWD, m 414 ± 24 438 ± 20 23 ± 16 484 ± 31 487 ± 24 3.0 ± 19.0
Lowest spO2, % 87.5 ± 1.4† 85.3 ± 1.5*,†† -2.2 ± 1.0 92.3 ± 0.5 92.5 ± 0.7 0.3 ± 0.6
Prmax, beats/minute 115.7 ± 3.8 117.4 ± 3.3 1.7 ± 2.4 114.4 ± 8.2 112.6 ± 4.3 -1.8 ± 8.6
Bsmax 3.9 ± 0.6 3.5 ± 0.5 -0.4 ± 0.4 3.4 ± 1.0 3.2 ± 1.0 -0.2 ± 0.3
symptom 49.1 ± 3.7 41.9 ± 3.5 -7.2 ± 4.1 46.1 ± 9.2 36.0 ± 7.5* -10.1 ± 3.9
Active 51.5 ± 5.1 45.9 ± 5.1 -5.6 ± 3.2 46.0 ± 11.6 31.9 ± 10.7* -14.1 ± 5.7
Impact 23.2 ± 3.3 18.9 ± 3.3 -4.3 ± 2.4 26.1 ± 7.6 19.1 ± 6.1 -7.0 ± 3.6
Total 38.6 ± 3.5 33.0 ± 3.2* -5.5 ± 2.4 37.5 ± 8.5 29.3 ± 7.4 -8.1 ± 4.0
Notes: Values are mean ± standard error of the mean. *P , 0.05 and **P , 0.01 versus pretreatment; †P , 0.05 versus nonemphysema phenotype; §P , 0.05 and§§ P<0.01 
versus salmeterol-treated group. 
Abbreviations: 6MWD, six-minute walking distance; PRmax, maximum pulse rate; BSmax, maximum Borg scale.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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significantly increased inspiratory capacity and FEV1, but did 
not reduce the decrease in inspiratory capacity following MPH,   
ie, MPH-induced dynamic hyperinflation, compared with 
baseline in patients with moderate-to-severe COPD. They 
suggested that increased baseline inspiratory capacity and 
lower operational lung volumes resulting from bronchodilation 
may blunt the effect of MPH-induced dynamic hyperinflation, 
because the extent of dynamic hyperinflation and decrease in 
inspiratory capacity with exercise is positively related to rest-
ing inspiratory capacity.7 Therefore, we corrected ∆IC30 and 
∆IC40 by IC20, and expressed these as percentage decreases 
in inspiratory capacity, ie, ∆IC30/IC20 and ∆IC40/IC20. Both 
∆IC30/IC20 and ∆IC40/IC20 were significantly reduced only for 
the emphysema phenotype in the tiotropium-treated group. 
Gelb et al22 also examined the relationship between visual 
emphysema score and changes in dynamic hyperinflation 
following MPH after 30 days plus 1.5 hours after the start 
of tiotropium in 29 patients with moderate-to-severe COPD, 
and demonstrated that the effects of tiotropium on dynamic 
hyperinflation were independent of underlying emphysema. 
In this study, a significant correlation between the low attenu-
ation area score and ∆IC40 or ∆IC40/IC20 was obtained in the 
tiotropium-treated group but not in the salmeterol-treated 
group. These different results may be due to the method of 
MPH used and the severity of emphysema. They directed the 
patients to achieve a breathing rate of 30 breaths per minute, 
which is lower than the maximum breathing rate according to 
our methods, and the emphysema score may be more severe 
in the emphysema-dominant phenotype in this study.
Reduction of dynamic hyperinflation following treatment 
with tiotropium in the emphysema dominant phenotype 
resulted in significantly improved exercise capacity and 
better health-related quality of life because improvement in 
dyspnea on effort or exercise tolerance following interven-
tion with pharmacotherapies has been demonstrated to be 
closely correlated with dynamic hyperinflation, but not with 
increased FEV1.23
In conclusion, tiotropium is more effective than salme-
terol regardless of the predominance of emphysema in stable 
COPD, giving more improvement in exercise tolerance and 
quality of life as a result of the reduction of dynamic hyper-
inflation in emphysema dominant COPD.
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